
UKUNQOBA
VICTORY!!! Ukunqoba kulomhlaba wezono (Victory in this sinful world) Igazi lika Jesu linyenyez’ Ukunqoba (The blood of Jesus brings victory.)
Filed under: General Problems | Leave a Comment »
UKUNQOBA
VICTORY!!! Ukunqoba kulomhlaba wezono (Victory in this sinful world) Igazi lika Jesu linyenyez’ Ukunqoba (The blood of Jesus brings victory.)
Filed under: General Problems | Leave a Comment »
How many times has a parent told their kid or you were told as a kid, when the kid did not agree with a parent’s decision, mandate, or edict and the parent’s only rationale was “BECAUSE” or “BECAUSE I SAID SO”. This article seems that the DEA is treating this physician and his request for a trial/using Psilocybin in END OF LIFE CANCER PTS. Like “kids”,” because we said so”
Lawyers for a doctor in Washington State seeking to legally use psilocybin for end-of-life care argue in a new federal appeals court filing that the Drug Enforcement Administration (DEA) failed to explain a key decision when it denied him access to the psychedelic. They’re asking judges to reverse that move, calling it arbitrary and capricious, and order the government to review the matter anew.
The opening brief filed in the U.S. Court of Appeals for the Ninth Circuit last week is the latest development in what’s become a years-long effort by Dr. Sunil Aggarwal and the Advanced Integrative Medical Science (AIMS) Institute to treat terminally ill cancer patients with psilocybin.
The new action takes aim against DEA’s decision in 2022 to deny Aggarwal’s requests to access psilocybin under state and federal right-to-try (RTT) laws, which give patients with terminal conditions the opportunity to try investigational medications that have not been approved for general use.
Washington State adopted a right-to-try law in 2017, and then-President Donald Trump signed the federal Right to Try Act the following year. Dozens of other states have enacted their own right-to-try policies.
Over the years, Aggarwal has presented DEA with multiple proposals in order either to legally cultivate or otherwise obtain psilocybin to treat his patients, arguing that the federal Controlled Substances Act (CSA) must accommodate a path to legally accessing the substance under RTT laws.
“DEA has rejected each request,” the new brief says, “but has never addressed the arguments that Dr. Aggarwal has raised in support of them.”
In 2022, DEA rejected a regulatory waiver that would have opened a path to Aggarwal legally obtaining psilocybin. The brief claims the agency had granted similar waivers in the past, but “DEA did not consider his arguments based on the agency’s precedent in this regard, nor did it provide a reasoned explanation for treating his request differently from similar ones it has dealt with in the past.”
“If DEA wants to disclaim authority to grant Dr. Aggarwal access to psilocybin under the CSA and RTT,” it continues, “it must provide a reasoned explanation for how that decision comports with the CSA and the agency’s own precedent.”
Instead, DEA’s decision “denied Petitioners’ request on grounds that permitting Dr. Aggarwal to access psilocybin as the Petition requested would not be ‘consistent with public health and safety,’” the brief says. “As support for that contention, DEA pointed to the statutory characteristics of schedule I drugs and claimed that the proposed activity—permitting psilocybin to be used therapeutically with dying patients under RTT’s terms—presented ‘too great a departure from current law.’”
The brief notes that the Ninth Circuit in October issued a ruling in Aggarwal’s favor on another matter, regarding a separate but related petition to reschedule psilocybin. In that case, judges said DEA failed to explain its reasoning when it denied that petition, and the court ordered the agency to provide a more complete justification, later denying Aggarwal’s request to instead send the petition to the Food and Drug Administration (FDA).
“For the same reason this Court remanded DEA’s inadequate denial letter in Aggarwal less than four months ago,” it says, “it must remand DEA’s Final Decision in this case as well.”
Lawyers for the AIMS Institute say in the opening brief that the court “should grant the petition for review, declare DEA’s Final Decision unlawful, set it aside, and remand this matter to the agency with instructions either to grant Dr. Aggarwal’s Petition or provide the reasoned explanation for denying it” as the law requires.
In short, “DEA denied Dr. Aggarwal’s Petition without addressing key arguments and reasons he raised, including ones based on the statutory text and DEA precedent,” the brief argues. “Was DEA’s Final Decision arbitrary and capricious? Yes.”
Amicus briefs in the case are expected later this week, on Thursday, according to Kathryn Tucker, one of the attorneys representing plaintiffs in the case, AIMS v. DEA 22-1568. DEA’s response deadline is April 8, with a reply from Aggarwal’s lawyers due the next month.
Aggarwal has been working since at least 2020 to find a way to legally obtain psilocybin for patients in palliative care, initially seeking to win permission from regulators under state and federal RTT laws.
When DEA rebuffed that request, Aggarwal sued. But in early 2022, a federal appellate panel dismissed the lawsuit, opining that the court lacked jurisdiction because DEA’s rejection of Aggarwal’s administrative request didn’t constitute a reviewable agency action.
The current Ninth Circuit cases stems from Aggarwal’s responses to that ruling. In February 2022, the doctor filed a formal petition with DEA to reschedule psilocybin from Schedule I to Schedule II under the federal Controlled Substances Act (CSA)—the denial of which is a reviewable action. He also applied for the regulatory waiver to obtain psilocybin.
DEA denied Aggarwal’s petition in September 2022 and rejected the waiver request the next month. The doctor’s Ninth Circuit cases challenge both decisions.
As Aggarwal’s efforts have made its way through the courts, a number of studies have strengthened the case for psilocybin’s legitimate medical use. In response, Congress late last year sent a defense bill to President Joe Biden (D) that contains provisions to fund studies into the therapeutic use of psychedelics such as psilocybin and MDMA for military service members.
A recent clinical trial published by the American Medical Association, meanwhile, found that psilocybin “displayed strong and persistent antidepressant effects” in people with bipolar II disorder, “with no signal of worsening mood instability or increased suicidality.”
In September of last year, researchers at Johns Hopkins and Ohio State universities published a report that linked psilocybin use with “persisting reductions” in depression, anxiety and alcohol misuse, as well as increases in emotional regulation, spiritual wellbeing and extraversion.
Those results were “highly consistent with a growing body of clinical trial, behavioral pharmacology, and epidemiological data on psilocybin,” authors of the study said. “Overall, these data provide an important window into the current resurgence of public interest in classic psychedelics and the outcomes of contemporaneous increases in naturalistic psilocybin use.”
Last August, a separate study from the American Medical Association (AMA) found that people with major depression experienced “clinically significant sustained reduction” in their symptoms after just one dose of psilocybin.
And a survey by Canadian researchers published in October said psilocybin use can help ease psychological distress in people who had adverse experiences as children. Researchers said psilocybin appeared to offer “particularly strong benefits to those with more severe childhood adversity.”
Canada, for its part, allowed four cancer patients in 2020 to become the nation’s first people in decades to legally possess psilocybin after being granted permission by the country’s health minister to use the substance for end-of-life care. Later that year, some healthcare professionals also gained the ability to legally possess and use psilocybin themselves.
A survey published earlier this year found that roughly 8 in 10 Canadians believe psilocybin is “a reasonable choice” for end-of-life care.
Filed under: General Problems | Leave a Comment »
I am a pharmacist writing this to spare you from suffering the same outcomes I have. This is a warning to not, under any circumstances, accept a position with cvs. It has ruined the lives of everyone I know that has worked for the company for any significant number of years. I don’t know any pharmacists in this company who have not had to take antidepressants or anti anxiety medications in addition to a slew of other medications for their generally ruined health. Now, to my horror, I have realized that is happening to me as well. I was once an athlete, and now find that my ability to maintain my health has been permanently stolen now that that my feet and knees are destroyed to the point that I can no longer run or even jog. I thought it wouldn’t happen to me. At least not this fast, but don’t underestimate the damage that forced standing for 10-14 hours per day will do to you. Of course, you wouldn’t have to stand all day if you weren’t forced to constantly be doing the jobs of three people. But you will, because the intentional business model of this company is to never provide enough staff. I want to emphasize this point, because it is the foundation of a hundred other problems you will have to endure as a result. You will be expected to work at a level 10 frenzy of stress and misery while trying to type prescriptions, fill prescriptions, verify prescriptions, all while you have anywhere from 1-10 calls simultaneously ringing, shipments to check in and put away, lines of customers up to 30 feet long, and the expectation to give vaccines. Do you think you could do this with 3 technicians? How about 2? No? How about 1? HOW ABOUT ZERO?
The staffing shortage has been absolutely crippling for years, and we were completely dumbfounded to find out that now, during the busiest part of the year, staffing hours have again been cut. So here that means most stores have 1 to 2 technicians working when 5 are actually needed. As a result, quality of service and safety are almost non existent. How would you like (on top of having an already miserable life courtesy of your employer) to have your license suspended for a safety violation when it was really the fault of your employer who provided absolutely none of the logistics required to do your job correctly and safely? Don’t be surprised if it happens because
And it is compounded by constant quitting. People are always quitting because it is so miserable, so you always have new and inexperienced people working, hence an even greater propensity for errors. And don’t think the state boards of pharmacy will do anything. We’ve tried. They sit firmly under the thumb of cvs. Anything they ever (extremely rarely) do is just for show and changes nothing. Most of the time they simply won’t respond.
Any pharmacy school that doesn’t caution their students about cvs is negligent. But because many of them are, I am speaking out to make sure you know that this company will ruin your physical and mental well being, your relationships, your career, your happiness, and your life.
Filed under: General Problems | 5 Comments »
WASHINGTON, DC – JUNE 23: U.S. Attorney General Merrick Garland (L) and DEA Administrator Anne Milgram at the Robert F. Kennedy headquarters building on June 23, 2023, in Washington, DC. Since its founding in 1973, The US Drug Enforcement Agency (DEA) has been a colossal institutional failure.
United States Capitol building, where the legislature of the United States, the United States Congress, and Senate meets, located in Washington, DC
Filed under: General Problems | 1 Comment »
Timothy E. King, MD “The Rat King Mother of All Fraud” Dr. King’s assertion that prescriptions of opioids should be deemed illegitimate if there is no objective evidence of functional improvement among patients. This premise, however, fails to account for the inherently subjective nature of pain – a critical factor in assessing the effectiveness of pain management.
DR. TIMOTHY KING, MD, “THE GREAT KING RAT’S” CAMPAIGN OF ALGORITHMIC EXTERMINATION
Filed under: General Problems | Leave a Comment »
UKUBONGA kulomhlaba wezono (Praise/Thanks in this sinful world) Igazi lika Jesu linyenyez’ ukubonga. (The blood of Jesus brings praise/thanks.) …THEN VICTORY!!!
Filed under: General Problems | Leave a Comment »
http://www.youtube.com/@stage4pancreaticcancer
Filed under: General Problems | Leave a Comment »
Filed under: General Problems | 2 Comments »
We have been homeless since 12/19/23.
Hotels are $100+ a night and isn’t a solution.
My husband served in both Iraq and Afghanistan multiple times in combat roles.
We lost all we had including our livestock.
The only time the U.S. Department of Veterans Affairs reaches out is when someone sees my posts and shares them…still with all of the resources I have we can’t find housing.
If you are in MD we are looking for immediate housing for our family of 4. Please share this & my other posts until someone follows through.
Thanks LinkedIn family! Gov. Wes Moore